Patent · US Active

Treatment of immune disease by mucosal delivery of antigents using genetically modified Lactobacillus

US8524246B2 · kind B2 · utility

2Cited by

37References

15Claims

0Family size

Assignee

ACTOGENIX N.V. · BE

Inventors

Pieter Rottiers · Zevergem, BE
Veerle Snoeck · Zingem, BE

Key dates

Filing date	Dec 19, 2012
Grant date	Sep 3, 2013
Priority date	—
Expiry date	Dec 19, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12R2001/225
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.